<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Chloramphenicol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00446</strong>&#160; (APRD00862, EXPT00942)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An antibiotic first isolated from cultures of <i>Streptomyces venequelae</i> in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00446/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00446/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00446.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00446.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00446.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00446.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00446.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00446">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Chlornitromycin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Laevomycetinum</td><td>Latin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Levomicetina</td><td>Spanish</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Levomycetin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Brochlor</td><td>Sanofi-Aventis</td></tr><tr><td>Chloramex</td><td>Actavis</td></tr><tr><td>Chlorocid</td><td>Egyt</td></tr><tr><td>Chlorocol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Chloromycetin</td><td>Pfizer</td></tr><tr><td>Chlorsig</td><td>Sigma</td></tr><tr><td>Fenicol</td><td>Alcon</td></tr><tr><td>Globenicol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Halomycetin</td><td>Wabosan</td></tr><tr><td>Oleomycetin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Sificetina</td><td>SIFI</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Actinac Lotion</td><td>Allantoin + Butoxyethyl Nicotinate + Chloramphenicol + Hydrocortisone Acetate + Sulfur</td></tr><tr><td>Chlorasone</td><td>Chloramphenicol + Prednisolone Acetate</td></tr><tr><td>Elase Chloromycetin</td><td>Chloramphenicol + Deoxyribonuclease Pancreatic + Fibrinolysin</td></tr><tr><td>Liquichlor</td><td>Chloramphenicol + Prednisolone + Squalane + Tetracaine</td></tr><tr><td>Ophthocort</td><td>Chloramphenicol + Hydrocortisone Acetate + Polymyxin B</td></tr><tr><td>Sopamycetin</td><td>Chloramphenicol + Hydrocortisone Acetate</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-bacterial-agents">Anti-Bacterial Agents</a></li>
<li><a href="/mesh/protein-synthesis-inhibitors">Protein Synthesis Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>56-75-7</td></tr><tr><th>Weight</th><td>Average: 323.129<br>Monoisotopic: 322.012326918</td></tr><tr><th>Chemical Formula</th><td>C<sub>11</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>WIIZWVCIJKGZOK-RKDXNWHRSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00446.gif?1265922773">show</a>(10.9 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenethylamines</td></tr><tr><th>Direct parent</th><td>Amphetamines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Nitrobenzenes; Nitro Compounds; Secondary Alcohols; Secondary Carboxylic Acid Amides; Nitronic Acids; Organic Oxoazanium Compounds; Primary Alcohols; Polyamines; Carboxylic Acids; Enolates; Organochlorides; Alkyl Chlorides</td></tr><tr><th>Substituents</th><td>nitronic acid; nitro compound; secondary carboxylic acid amide; carboxamide group; secondary alcohol; carboxylic acid derivative; enolate; carboxylic acid; organic oxoazanium; primary alcohol; polyamine; organochloride; organonitrogen compound; organohalogen; alcohol; amine; alkyl halide; alkyl chloride</td></tr><tr><th>Classification description</th><td>This compound belongs to the amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used in treatment of cholera, as it destroys the vibrios and decreases the diarrhea. It is effective against tetracycline-resistant vibrios. It is also used in eye drops or ointment to treat bacterial conjunctivitis.</td></tr><tr><th>Pharmacodynamics</th><td>Chloramphenicol is a broad-spectrum antibiotic that was derived from the bacterium Streptomyces venezuelae and is now produced synthetically. Chloramphenicol is effective against a wide variety of microorganisms, but due to serious side-effects (e.g., damage to the bone marrow, including aplastic anemia) in humans, it is usually reserved for the treatment of serious and life-threatening infections (e.g., typhoid fever). Chloramphenicol is bacteriostatic but may be bactericidal in high concentrations or when used against highly susceptible organisms. Chloramphenicol stops bacterial growth by binding to the bacterial ribosome (blocking peptidyl transferase) and inhibiting protein synthesis.</td></tr><tr><th>Mechanism of action</th><td>Chloramphenicol is lipid-soluble, allowing it to diffuse through the bacterial cell membrane. It then reversibly binds to the L16 protein of the 50S subunit of bacterial ribosomes, where transfer of amino acids to growing peptide chains is prevented (perhaps by suppression of peptidyl transferase activity), thus inhibiting peptide bond formation and subsequent protein synthesis.</td></tr><tr><th>Absorption</th><td>Rapidly and completely absorbed from gastrointestinal tract following oral administration (bioavailability 80%). Well absorbed following intramuscular administration (bioavailability 70%). Intraocular and some systemic absorption also occurs after topical application to the eye.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Plasma protein binding is 50-60% in adults and 32% is premature neonates.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, with 90% conjugated to inactive glucuronide.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral, mouse: LD<sub>50</sub> = 1500 mg/kg; Oral, rat: LD<sub>50</sub> = 2500 mg/kg. Toxic reactions including fatalities have occurred in the premature and newborn; the signs and symptoms associated with these reactions have been referred to as the gray syndrome. Symptoms include (in order of appearance) abdominal distension with or without emesis, progressive pallid cyanosis, vasomotor collapse frequently accompanied by irregular respiration, and death within a few hours of onset of these symptoms.</td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9157</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9366</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7367</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7305</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9216</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8822</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9477</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7775</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8934</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5936</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8994</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8682</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.5483
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.5053
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2247 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9658
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8764
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>John j ferrante</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Parkedale pharmaceuticals inc</li>
<li>Armenpharm ltd</li>
<li>Parke davis pharmaceutical research div warner lambert co</li>
<li>Altana inc</li>
<li>Pharmafair inc</li>
<li>Allergan pharmaceutical</li>
<li>Alcon laboratories inc</li>
<li>Akorn inc</li>
<li>Optopics laboratories corp</li>
<li>Elkins sinn div ah robins co inc</li>
<li>App pharmaceuticals llc</li>
<li>Gruppo lepetit spa sub merrell dow pharmaceuticals inc</li>
<li>Angus chemical co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://www.darbydental.com">Darby Dental Supply Co. Inc.</a></li>
<li><a href="http://www.giv.com">General Injectables and Vaccines Inc.</a></li>
<li>Gruppo Lepetit SPA</li>
<li>Ivax Pharmaceuticals</li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.pccarx.com">Professional Compounding Centers America LLC</a></li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Ophthalmic</td><td></td></tr><tr><td>Ointment</td><td>Ophthalmic</td><td></td></tr><tr><td>Powder, for solution</td><td>Intramuscular</td><td></td></tr><tr><td>Solution</td><td>Ophthalmic</td><td></td></tr><tr><td>Solution / drops</td><td>Ophthalmic</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00414">Acetohexamide</a></td><td>Chloramphenicol may increase the effect of sulfonylurea, acetohexamide.</td></tr><tr><td><a href="/drugs/DB00241">Butalbital</a></td><td>Barbiturates such as butalbital may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates. Monitor for decreased serum concentrations/therapeutic effects of chloramphenicol if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. In addition, monitor for increased effects of barbiturates if chloramphenicol is initiated/dose increased, or decreased effects if chloramphenicol is discontinued/dose decreased. </td></tr><tr><td><a href="/drugs/DB00672">Chlorpropamide</a></td><td>Chloramphenicol may increase the effect of sulfonylurea, chlorpropamide.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Chloramphenicol may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>Increases phenytoin, modifies chloramphenicol</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Increases phenytoin, modifies chloramphenicol</td></tr><tr><td><a href="/drugs/DB01120">Gliclazide</a></td><td>Chloramphenicol may increase the effect of sulfonylurea, gliclazide.</td></tr><tr><td><a href="/drugs/DB01067">Glipizide</a></td><td>Chloramphenicol may increase the effect of sulfonylurea, glipizide.</td></tr><tr><td><a href="/drugs/DB01289">Glisoxepide</a></td><td>Chloramphenicol may increase the effect of sulfonylurea, glisoxepide.</td></tr><tr><td><a href="/drugs/DB01016">Glyburide</a></td><td>Chloramphenicol may increase the effect of sulfonylurea, glibenclamide.</td></tr><tr><td><a href="/drugs/DB01382">Glycodiazine</a></td><td>Chloramphenicol may increase the effect of sulfonylurea, glycodiazine.</td></tr><tr><td><a href="/drugs/DB08815">Lurasidone</a></td><td>Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. </td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>Increases phenytoin, modifies chloramphenicol</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Increases phenytoin, modifies chloramphenicol</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin decreases the effect of chloramphenicol</td></tr><tr><td><a href="/drugs/DB06207">Silodosin</a></td><td>Chloramphenicol is a strong inhibitor of CYP3A4 may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects. Combination therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Chloramphenicol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Chloramphenicol therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00599">Thiopental</a></td><td>Chloramphenicol may increase the serum concentration of Thiopental by decreasing Thiopental metabolism. Thiopental may decrease the serum concentration of Chloramphenicol by increasing Chloramphenicol metabolism. Monitor for changes in therapeutic effects of both agents if concomitant therapy is initiated, discontinued or doses are adjusted. </td></tr><tr><td><a href="/drugs/DB00839">Tolazamide</a></td><td>Chloramphenicol may increase the effect of sulfonylurea, tolazamide.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Chloramphenicol may increase the effect of sulfonylurea, tolbutamide.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take on an empty stomach.</li></ul></td></tr></tbody></table>